Capravirine: Phase II

Agouron, a subsidiary of Warner Lambert Co. (WLA, Morris Plains, N.J.), said that in a 36-patient Phase II trial, both twice daily and three times per day regimens of capravirine monotherapy (700-2100 mg per dose) showed comparable 1.1-1.69 log decreases in HIV viral load to each other and to a control arm treated with the combination of Agouron's Viracept nelfinavir, Glaxo Wellcome's Retrovir zidovudine AZT and BioChem Pharma's Epivir lamivudine 3TC. In a separate 40-patient Phase II study, Agouron said that Capravirine was well-tolerated and showed good pharmacokinetics in combination with either Retrovir or Bristol-Myers Squibb's Zerit stavudine d4T plus either Viracept or Merck's Crixivan indinavir. Data were presented at the Retroviruses and Opportunistic Infections conference in San Francisco. ...